60 results
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
programs, partially offset by decreased batoclimab program-specific research and development costs (including contract manufacturing costs).
IPR&D … , and increased batoclimab program-specific research and development costs (including contract manufacturing costs), partially offset by lower costs
S-3ASR
IMVT
Immunovant Inc
9 Nov 23
Automatic shelf registration
8:49am
Fees Previously Paid
Total Fee Offsets
Net Fee Due
Table 2: Fee Offset Claims and Sources
Registrant
or Filer
Name
Form
or
Filing
Type
File …
Number
Initial
Filing
Date
Filing
Date
Fee
Offset
Claimed
Security
Type
Associated
with Fee
Offset
Claimed
Security
Title
Associated
with Fee
8-K
EX-99.1
IMVT
Immunovant Inc
9 Nov 23
Results of Operations and Financial Condition
7:06am
offset by decreased batoclimab program-specific research and development costs (including contract manufacturing costs) and lower costs related … -related expenses, market research costs, and information technology costs, partially offset by lower legal and other professional fees.
Net Loss: Net
424B5
qgy8y6a7asnpf29
29 Sep 23
Prospectus supplement for primary offering
4:48pm
424B5
dy4yfd4g644
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
bqai atofoyf5
10 Aug 23
Results of Operations and Financial Condition
7:10am
8-K
EX-99.1
qoei9bh6yg5r
22 May 23
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
lx0gu39bn
4 Nov 22
Results of Operations and Financial Condition
7:15am
424B5
lgor48b
5 Oct 22
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
dz99k68j12zd x08t
5 Aug 22
Results of Operations and Financial Condition
7:07am
8-K
EX-99.1
iou6y1
4 Feb 22
Company Ended the Quarter With Cash of Approximately $527.0 Million
7:09am